This eLife study builds a mouse hemogenic gastruloid (haemGx) that is claimed to recapitulate time-ordered yolk-sacβlike vs AGM-like hematopoietic waves from hemogenic endothelium, then tests MNX1 overexpression as a developmental leukemia driver for infant MNX1-r AMLβwhile reporting only low-level, niche-dependent engraftment after adrenal implantation.
The field knows embryonic hematopoiesis involves staged waves and endothelial-to-hematopoietic transition (EHT), with yolk sac and AGM contributing at different times and niches. This paperβs novelty is to operationalize those stages in a 3D, time-resolved in vitro system and then ask whether a developmental AML driver (MNX1-r) targets an early window (reported at the YS endothelial-to-EMP transition stage).
A strict disproof program would include: (i) showing that EZH2 inhibition does not specifically affect the claimed early wave, (ii) demonstrating that MNX1-OE does not alter patient-MNX1-r-like signature enrichment nor clonogenic transformation patterns, and (iii) recovering robust functional long-term repopulating HSC activity without reliance on an adrenal niche (or at least showing cell-intrinsic maturation sufficient for canonical engraftment). The study partially addresses (i) and (ii) with EZH2 perturbation and signature/proxy functional replating, but (iii) remains limited by low engraftment frequency and apparent niche dependence.
Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.